COMMUNIQUÉS West-GlobeNewswire

Stemline Therapeutics to Present at the 37th Annual J.P. Morgan Healthcare Conference
02/01/2019
NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (NASDAQ:STML), a biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, announced today that [...]
Aptose Biosciences to Present at Biotech Showcase™ 2019 Conference
02/01/2019
SAN DIEGO and TORONTO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of [...]
Resonant Inc. Enters 2019 with Over 20 Devices Accepted by Customers
02/01/2019
Includes first 5G device Doubles the number of devices accepted by customers announced at the beginning of 2018 GOLETA, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Resonant Inc. (NASDAQ: RESN), a leader in transforming [...]
Cybrexa Therapeutics Selects Lead Clinical Candidate CBX-11, Combining its alphalex™ Technology with an Approved PARP Inhibitor to Treat Various Solid Tumors in Combination with Chemotherapy
02/01/2019
CBX-11 selected based on robust efficacy and safety in combination with chemotherapy demonstrated in preclinical models Positive pre-IND Meeting with FDA supports on track plan to file IND in Q4 2019 NEW HAVEN, Conn., [...]
Kamada Announces Preliminary Revenue for Fourth Quarter and Full-Year 2018
02/01/2019
Full-Year 2018 Revenue Expected to be Between $113 Million and $115 Million Anticipated Revenues Exceed Current Revenue Guidance of $102 Million to $108 Million Expected Full-Year 2018 Total Revenue Would Represent [...]
Sunesis Pharmaceuticals Announces Advancement into 100mg Cohort of Phase 1b/2 Trial of Vecabrutinib in Patients with CLL and Other B-Cell Malignancies
02/01/2019
- 50 mg Cohort Completed - - Clinical Update Expected in the Second Quarter of 2019 - SOUTH SAN FRANCISCO, Calif., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Sunesis Pharmaceuticals, Inc. (Nasdaq:SNSS) today announced that the [...]
Cara Therapeutics Announces No Modifications in Trial Size After Completion of Interim Statistical Assessment For KALM-1 Phase 3 Trial Of KORSUVA™ Injection in Hemodialysis Patients with Pruritus
02/01/2019
- Trial continues as planned with enrollment target of 350 patients - - Top-line data readout expected in the first half of 2019 - STAMFORD, Conn., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA [...]
Tonix Pharmaceuticals to Present at Upcoming Investor Conferences and Participate in Featured Panel Discussion
02/01/2019
NEW YORK, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company) announced today that Seth Lederman, M.D., President and Chief Executive Officer of Tonix, will [...]
BioCryst Initiates Phase 1 Clinical Trial of Galidesivir
02/01/2019
RESEARCH TRIANGLE PARK, N.C., Jan. 02, 2019 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced the dosing of the first subject in a randomized, placebo-controlled phase 1 clinical trial to [...]
Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency
02/01/2019
SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Arcturus Therapeutics Ltd. (NASDAQ: ARCT), a leading RNA medicines company focused on the development and commercialization of therapeutics towards rare, liver and [...]
ProQR Receives Fast Track Designation from FDA for QR-421a for Usher Syndrome Type 2
02/01/2019
LEIDEN, Netherlands & CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the [...]
Holding(s) in Company
02/01/2019
TR-1: S tandard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i 1a. Identity of the issuer or the [...]
ASLAN Pharmaceuticals Completes Enrolment for Global Pivotal TreeTopp Study Ahead of Schedule
02/01/2019
Topline data from largest global, placebo-controlled study in second line biliary tract cancer expected in the second half of 2019 SINGAPORE, Jan. 02, 2019 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (NASDAQ:ASLN, TPEx: [...]
ObsEva SA to Participate in JP Morgan Healthcare Conference January 7-10, 2019
02/01/2019
Geneva, Switzerland and Boston – January 2, 2019 - ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for serious [...]
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/01/2019
CAMBRIDGE, Mass., Dec. 31, 2018 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a leader in precision genetic medicine for rare diseases, granted equity awards on December 31, 2018, that were previously [...]
Adamis Pharmaceuticals Submits New Drug Application to FDA for Its Naloxone Pre-Filled Syringe
31/12/2018
SAN DIEGO, Dec. 31, 2018 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration for its naloxone pre [...]
U.S. Food and Drug Administration Approves Portola Pharmaceuticals’ Prior Approval Supplement for Andexxa® Generation 2 Manufacturing Process
31/12/2018
– Expands Patient Access to Andexxa, the First and Only Antidote for Reversal of the Factor Xa Inhibitors Rivaroxaban or Apixaban – – Full Commercial Launch to Begin January 2019 – SOUTH SAN FRANCISCO, Calif., Dec. 31, [...]
Green Growth Brands Reaffirms Commitment to Takeover Aphria Inc.
31/12/2018
Welcomes early expressions of interest from a growing number of frustrated Aphria shareholders who want a way out of a failed investment Offer valued at C$11.00 per Aphria share represents significant and compelling [...]
Merus annonce les résultats financiers du troisième trimestre 2018 et fait le point sur son activité
31/12/2018
Jalons cliniques des quatre principaux programmes Biclonics® prévus en 2019 Les liquidités devraient être suffisantes pour financer les activités du deuxième trimestre 2021 UTRECHT, Pays-Bas, 31 déc. 2018 (GLOBE [...]

Pages